Psychiatry AtlasMedication guide · United States

Antipsychotic medicine

Olanzapine (Zyprexa, Zyprexa Zydis, Weltruza)

Generic name
olanzapine
Brand names
Zyprexa; Zyprexa Zydis; Weltruza
Medication class
Antipsychotic medicine
Forms covered
oral tablets; orally disintegrating tablets; Weltruza extended-release subcutaneous injection

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

Show more (3)

FDA Boxed Warning

Selected oral products and Weltruza subcutaneous injection; other injections have separate labeling.

Oral olanzapine increases the risk of death in older adults with dementia-related psychosis and is not approved for that use. When used with fluoxetine, also consult the combination’s boxed warning. Weltruza carries the same dementia-related mortality warning and is not approved for dementia-related psychosis.

Oral olanzapine treats schizophrenia and specific phases of bipolar I disorder; certain depressive conditions are approved uses only with fluoxetine. Weltruza is a separate monthly injection for schizophrenia in adults. Products have different indications and instructions.

Weltruza (extended-release subcutaneous injection for adults with schizophrenia).

What to expect: Full benefit may take several weeks or longer.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Schizophrenia — Adults and adolescents aged 13–17. The label asks clinicians to consider the greater adolescent metabolic risk when choosing treatment.oral tablets; orally disintegrating tablets.
  • Acute manic or mixed episodes in bipolar I disorder — Adults and adolescents aged 13–17. Oral monotherapy; adjunctive use with lithium or valproate is supported in adults.oral tablets; orally disintegrating tablets.
  • Maintenance treatment of bipolar I disorder — Adults. Continuing oral monotherapy after response, with periodic reassessment.oral tablets; orally disintegrating tablets.
  • Bipolar I depressive episodes, with fluoxetine — Adults and children/adolescents aged 10–17. The indication applies to the combination, not olanzapine alone. Read both products’ safety information.oral tablets; orally disintegrating tablets.
  • Treatment-resistant depression, with fluoxetine — Adults. Combination indication after inadequate response to two adequate antidepressant trials in the current episode; not olanzapine monotherapy.oral tablets; orally disintegrating tablets.
  • Schizophrenia — Weltruza — Adults. Separate monthly injection administered by a healthcare professional after oral tolerability is established. Do not transfer the oral bipolar indications to this product.Weltruza extended-release subcutaneous injection.

Other uses (off-label)

Off-label means a medicine is prescribed for a use, age group or form that is not included in its FDA approval.

  • Chemotherapy-associated nausea and vomiting — People receiving selected cancer treatments under an oncology team. An oncology use described by MedlinePlus; it is not among the approved Zyprexa indications in this product label.oral tablets; orally disintegrating tablets.

What should I expect?

Full benefit may take several weeks or longer. Review changes in the symptoms being treated alongside alertness, appetite, and daily functioning; sleepiness alone does not show that the underlying condition has improved.

Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.

How do I take it safely?

Take oral tablets as prescribed, usually once daily, with or without food. For Zydis, peel the foil with dry hands and place the whole tablet in the mouth immediately; it can be swallowed with or without a drink.

Combination treatment with fluoxetine has additional instructions and risks. Zyprexa Relprevv is a separate long-acting intramuscular product requiring at least three hours of observation after each injection. Weltruza is given once monthly under the skin of the abdomen by a healthcare professional for schizophrenia in adults, after tolerability to oral olanzapine has been established. Its label does not specify Relprevv’s three-hour observation requirement. These products must not be exchanged without a prescribing plan.

Keep checks of weight, blood sugar, blood fats, blood pressure, bowel function, and movements. Discuss liver disease, a history of low white cells, falls, or trouble swallowing. Do not drive until you know how the medicine affects you.

The US Zyprexa monotherapy label lists no formal contraindications; combination therapy must also satisfy the other medicine’s contraindications.

Fluvoxamine can raise olanzapine exposure, while carbamazepine can lower it; cigarette smoking can also increase clearance. Tell the prescriber about starting or stopping smoking. Alcohol, sedatives and medicines that lower blood pressure can add to impairment or dizziness. Anticholinergic drugs can worsen constipation and related complications. Olanzapine may oppose levodopa and dopamine agonists. Fluoxetine combination therapy requires its own interaction review, including the restrictions associated with fluoxetine.

Third-trimester exposure to antipsychotics can cause newborn movement or withdrawal symptoms, including breathing and feeding difficulties. Discuss pregnancy plans and relapse risk rather than stopping abruptly. Olanzapine is present in breast milk; exposed infants should be assessed for excessive sleepiness, irritability, poor feeding or unusual movements.

Oral schizophrenia and manic-episode approvals begin at age 13; the fluoxetine combination has a different age limit for bipolar depression. Older adults may be more sensitive to sedation, low blood pressure and falls.

Do not stop olanzapine suddenly or change between oral and injectable products without a prescriber’s plan. For a forgotten oral dose, follow the patient instructions and do not double the next dose. Ongoing treatment needs periodic reassessment of benefit, metabolic effects and the lowest effective dose. If treatment has been interrupted or several doses missed, ask the treating team how to resume safely; the long-acting injection has its own appointment and missed-dose rules.

What side effects should I know about?

  • Increased appetite, weight gain, sleepiness, dizziness, dry mouth and constipation.
  • Tremor, restlessness or other movement symptoms can occur; glucose and lipid changes may be detected through tests.
  • Weltruza can also cause headache and injection-site pain, redness, itching, swelling or firmness.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • A rash with fever, swollen glands or facial swelling may indicate DRESS, a potentially serious multi-organ drug reaction, and needs urgent assessment.
  • Severe constipation with abdominal pain, vomiting or swelling, or marked thirst with weakness or confusion, needs prompt medical assessment.
  • Seek emergency care for high fever with severe stiffness or confusion, trouble breathing, collapse, a seizure, or a suspected overdose. New involuntary movements, severe restlessness, or symptoms of high blood sugar need prompt medical assessment.
  • After an olanzapine injection, severe sleepiness, confusion, difficulty walking or speaking, or fainting needs urgent medical assessment; breathing trouble or inability to wake requires emergency care.

What else should I know to stay safe?

  • Monitor weight, blood sugar, blood fats, blood pressure, bowel function, and movements. Adolescents can have greater weight and blood-fat changes. Review liver disease, low white-cell counts, falls, and swallowing problems. Combination treatment with fluoxetine, lithium, or valproate must also satisfy the other medicine’s precautions.
  • Fluvoxamine can raise olanzapine levels; carbamazepine and cigarette smoking can lower them. Tell the prescriber before starting or stopping smoking. Alcohol, sedatives, blood-pressure medicines, and medicines that worsen constipation can add risk; olanzapine can oppose levodopa and dopamine medicines.
  • Plan stopping, restarting, or changing formulation with the prescriber. Discuss pregnancy and breastfeeding: later-pregnancy exposure can cause newborn movement or withdrawal problems, and exposed breastfed infants need attention to feeding, alertness, and unusual movements. Older adults are more vulnerable to sedation, low blood pressure, and falls.
  • Short-acting injections: US prescribing information advises against combining intramuscular olanzapine with injected benzodiazepines because of potentially excessive sedation and suppression of breathing and circulation. This precaution is separate from the dementia-related mortality boxed warning. The injection is labeled for intramuscular use only, not intravenous use.
  • Weltruza has a dementia-related mortality boxed warning. Its risk of post-injection delirium/sedation syndrome, a reaction involving severe confusion or sleepiness, is unknown; the absence of cases in premarketing trials does not establish zero risk. Call the treating team promptly if an injection appointment is missed.
More about injections used in emergency care

Evidence update — injectable olanzapine and benzodiazepines: A 2024 study reviewed records from 693 emergency-department patients given two injections within 60 minutes. A breathing tube was needed in 5 of 144 patients receiving olanzapine plus a benzodiazepine (3.5%), compared with 21 of 549 receiving two olanzapine doses (3.8%).

This observational study did not detect a significant difference; it does not establish equal safety or exclude serious harm. It studied short-acting injections, not tablets or long-acting depot treatment.

US emergency-care guidance: The American College of Emergency Physicians (ACEP) supports an atypical antipsychotic with midazolam for severe agitation in adults in the emergency department. This is setting-specific guidance, not a change to product labeling or a general recommendation for routine inpatient or home use. It provides no specific drug recommendation for people older than 65. Product-specific warnings and professional monitoring remain necessary.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • A change in cigarette smoking can change olanzapine levels. Tell the prescriber when you start or stop smoking so the treatment can be reviewed.
  • Appetite, weight, blood sugar, and cholesterol deserve attention from the start. Adolescents can be especially vulnerable to weight and blood-fat changes.

How does it work?

Olanzapine changes how brain cells respond to several chemical messengers, including dopamine and serotonin. It attaches to receptors, proteins that receive these messages, and blocks activation at several types. These actions are well described, but they do not yet provide a complete explanation of its treatment benefits.

Explore medication science

How was this medicine developed?

The FDA approved Zyprexa in 1996. Later development added dissolving tablets and other delivery forms, as well as specific bipolar uses. Depression approvals with fluoxetine belong to the combination rather than to olanzapine alone.

How do I say the name?

Olanzapine: oh-LAN-zuh-peen. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. MedlinePlus: olanzapine
  2. Zyprexa: current US prescribing information (10/2026)
  3. Drugs@FDA: Zyprexa approval and regulatory history
  4. Cole et al. (2024): injectable olanzapine with or without a benzodiazepine in the emergency department
  5. ACEP clinical policy: severe agitation in adult emergency-department patients (approved October 2023; published January 2024)
  6. Weltruza: FDA prescribing information and Medication Guide (October 2026)
  7. Olanzapine: Uses, Dosage, Side Effects, Warnings - Drugs.com
  8. What Is a Neurotransmitter?
  9. PubChem: olanzapine, CID 135398745
  10. MedlinePlus: olanzapine injection
  11. FDA: Seroquel immediate-release label and Medication Guide
  12. ISMP List of Confused Drug Names
  13. ZYPREXA
  14. Frequently Asked Questions about Labeling for Prescription Medicines | FDA

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top